Table 2.
Comparison of several factors for patients who were divided by the response to first-line GP chemotherapy
| Good (n = 30) | Poor (n = 15) | P | |
|---|---|---|---|
| Age, median (year, range) | 64.0 (58.5–73.0) | 66.0 (64.0–71.0) | 0.289 |
| Type of platinum compound used as the first-line | 0.695 | ||
| Cisplatin | 23 (76.7 %) | 13 (86.7 %) | |
| Carboplatin | 7 (23.3 %) | 2 (13.3 %) | |
| Response to the first-line GP chemotherapy | - | ||
| CR | 11 (36.7 %) | - | |
| PR | 19 (63.3 %) | - | |
| SD | - | 5 (33.3 %) | |
| PD | - | 10 (66.6 %) | |
| TTP of the first-line GP chemotherapy, median (months, range) | 11.6 (7.8–14.2) | 3.13 (2.2–5.0) | <0.001 |
| Cycles of the first-line GP chemotherapy, median (range) | 6.0 (6.0–7.3) | 4.0 (3.0–4.0) | <0.001 |
| TFI between GP and MVAC, median (months, range) | 2.5 (0.7–9.9) | 1.7 (0.6–3.4) | 0.202 |
| Primary tumor site | >0.999 | ||
| Bladder | 20 (66.7 %) | 10 (66.7 %) | |
| Ureter or renal pelvic | 4 (13.3 %) | 2 (13.3 %) | |
| Ureter or renal pelvic with bladder | 6 (20.0 %) | 3 (20.0 %) | |
| Clinical N stage | 0.453 | ||
| N0 | 4 (13.3 %) | 2 (13.3 %) | |
| N1 | 5 (16.7 %) | 3 (20.0 %) | |
| N2 | 11 (36.7 %) | 8 (53.3 %) | |
| N3 | 10 (33.3 %) | 2 (13.3 %) | |
| Distant metastatic site at the time of MVAC administration | |||
| Lung | 15 (50.0 %) | 6 (40.0 %) | 0.752 |
| Bone | 10 (33.3 %) | 6 (40.0 %) | 0.746 |
| Liver | 8 (26.7 %) | 1 (6.7 %) | 0.234 |
| Others | 4 (13.3 %) | - (0.0 %) | 0.285 |
| Hemoglobin (g/dL, range) | 11.3 (10.5–11.9) | 11.0 (9.8–11.3) | 0.032 |
| Absolute neutrophil count (/dL, range) | 3751.5 (2733.0–5337.0) | 3524.0 (2415.0–5252.0) | 0.596 |
| Platelet count, 103(/dL, range) | 219.5 (184.8–291.5) | 216.0 (169.0–311.0) | 0.952 |
| eGFR (ml/min, range) | 62.6 (52.6–75.3) | 71.5 (47.0–84.7) | 0.739 |
| Serum bilirubin (mg/dL, range) | 0.4 (0.3–0.6) | 0.3 (0.3–0.4) | 0.047 |
| Serum albumin (g/dL, range) | 4.0 (3.8–4.4) | 3.8 (3.5–4.2) | 0.159 |
| ECOG performance status (PS) | 0.275 | ||
| PS 0 | 12 (40.0 %) | 8 (53.3 %) | |
| PS 1 | 16 (53.3 %) | 7 (46.7 %) | |
| PS 2 | 2 (6.7 %) | - (0.0 %) | |
GP gemcitabine platinum, CR complete response, PR partial response, SD stable disease, PD progression disease, TTP time to progression, TFI treatment free interval, MVAC methotrexate vinblastine Adriamycin cisplatin, eGFR estimated glomerular filtration rate, ECOG Easton Cooperative Oncologic Group, Boldface significant 2-tailed